University of Pittsburgh, Department of Medicine, Pittsburgh, PA 15213, USA.
Bone. 2010 Apr;46(4):1006-10. doi: 10.1016/j.bone.2009.12.025. Epub 2010 Jan 4.
In addition to bone mineral density (BMD), trabecular microstructure contributes to skeletal strength. Our goal was to examine changes in trabecular microstructure in women on therapy.
We followed 10 postmenopausal women receiving a bisphosphonate, risedronate (35 mg once weekly), over 12 months and examined trabecular microarchitecture with high resolution wrist MR images (hr-MRI). MRI parameters included bone volume/total volume (BV/TV), surface density (representing plates), curve density (representing rods), surface-to-curve ratio and erosion index (depicting deterioration). We assessed BMD of the spine, hip and radius and markers of bone turnover.
Women had been receiving bisphosphonate therapy for 43+/-9 months (mean+/-SD) prior to the first MRI. Indices of hr-MRI demonstrated improvement in surface-to-curve ratio (13.0%) and a decrease in erosion index (12.1%) consistent with less deterioration (both p<0.05). BMD of the spine, hip and radius and markers of bone turnover remained stable. Parameters of hr-MRI were associated with 1/3 distal radius BMD (correlation coefficient 0.71 to 0.86, p<0.05).
We conclude that hr-MRI of the radius demonstrates improvements in trabecular microstructure not appreciated by conventional BMD and provides additional information on parameters that contribute to structural integrity in patients on antiresorptive therapy.
除了骨密度(BMD)之外,小梁微结构也有助于骨骼强度。我们的目标是研究接受治疗的女性小梁微结构的变化。
我们对 10 名绝经后妇女进行了随访,这些妇女接受了双膦酸盐雷奈酸锶(每周 35 毫克)治疗 12 个月,并使用高分辨率腕部磁共振成像(hr-MRI)检查了小梁微结构。MRI 参数包括骨体积/总体积(BV/TV)、表面密度(代表板)、曲线密度(代表杆)、表面与曲线比和侵蚀指数(代表恶化)。我们评估了脊柱、臀部和桡骨的 BMD 以及骨转换标志物。
在第一次 MRI 之前,女性已经接受了 43+/-9 个月(平均值+/-标准差)的双膦酸盐治疗。hr-MRI 指数显示表面与曲线比改善(13.0%),侵蚀指数降低(12.1%),表明恶化程度降低(均 p<0.05)。脊柱、臀部和桡骨的 BMD 以及骨转换标志物保持稳定。hr-MRI 参数与 1/3 远端桡骨 BMD 相关(相关系数为 0.71 至 0.86,p<0.05)。
我们的结论是,桡骨的 hr-MRI 显示出小梁微结构的改善,这是常规 BMD 无法评估的,并且提供了有关有助于抗吸收治疗患者结构完整性的参数的额外信息。